The CodeBreaK100 trial demonstrated an objective response of 37% and a complete response rate of 3.2% with sotorasib in patients with previously treated KRAS p.G12C-mutated NSCLC [157]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.